Navigation Links
BHR Pharma Statement on Brain Injury Awareness Month - Better Awareness, Treatment, Research Needed Now

HERNDON, Va., March 23 /PRNewswire-USNewswire/ -- Julian Bailes, MD, BHR Pharma, LLC's Lead Advisor for Moderate Traumatic Brain Injury (TBI) today released the following statement regarding Brain Injury Awareness Month:

"BHR Pharma salutes the Brain Injury Association of America (BIAA) for its concerted efforts to raise awareness about the dangers and proper treatment of concussions everywhere from playgrounds to professional sports arenas.  BIAA is correctly pointing out through its advocacy that concussions are TBIs, with the potential for serious, debilitating and long-term effects.  

"TBI is defined as a non-degenerative, non-congenital insult to the brain from an external mechanical force, possibly leading to temporary or permanent impairments of cognitive, physical and psychosocial functions with an associated diminished or altered state of consciousness.

"According to the Centers for Disease Control and Prevention, U.S. hospital emergency departments treat an estimated 3.8 million sports- and recreation-related concussions annually.  It is time that athletes of all ages and their coaches completely move away from 'play through pain' attitudes in relation to concussions.  

"During Brain Injury Awareness Month, it is also important to recognize that traumatic brain injuries range from concussions to severe head trauma, such as injuries sustained in traffic accidents – a leading cause of TBI in the world, accounting for 40-50 percent of hospitalizations.  Approximately 1.7 million Americans per year suffer a traumatic brain injury, resulting in 52,000 deaths, 275,000 hospitalizations and 80,000 cases of long-term disability.

"Although the prognosis for patients that are hospitalized with a severe form of TBI is generally not very promising, current research is pointing to a future of treatment that potentially offers these patients and their families hope for better quality of life.  In particular, two multi-center, Phase 3 clinical trials are worth noting.  They are BHR Pharma's SyNAPSe ( and Emory University's ProTECT III ( trials.  Both are evaluating the safety and effectiveness of progesterone as a neuroprotective agent for treating moderate to severe TBI.

"The success of these studies requires that study staff quickly reach family members to request permission to enroll their loved one in the trial. Although it may occur at a time of great personal pain and confusion, the families' difficult decision-making – usually in an emergency room setting – will go a long way in helping advance TBI treatment."


Back to top



Copyright©2010 PR Newswire.
All rights reserved

Related medicine news :

1. Drug Information Association (DIA) Announces New Clinical Safety and Pharmacovigilance Certificate Program
2. Huifeng Bio-Pharmaceutical Provides Preliminary 2009 Financial Results and 2010 Guidance
3. Octapharma Accepting Applications for Research Grants Through March 31
4. Two Long-Term Care Organizations Select Remedi SeniorCare for Pharmacy Services
5. Possible pharmacological target(s) identified in pediatric OSA
6. Therapure Biopharma Inc. and Akorn, Inc. Announce Strategic Supply Contract
7. Six Key Areas of Learning for Pharmaceutical and Healthcare Marketing in 2010
8. Frost & Sullivan Ghanaian Pharmaceutical Industry Innovation & Advancement Award Conferred on LaGray Chemical Company
9. Viscira Expands Interactive Solutions to Reduce Marketing Expenses for Pharmaceutical Companies in Challenging Economic Times
10. Nutra Pharma Announces Fourth Quarter Sales for its Over-the-Counter (OTC) Pain Reliever, Cobroxin
11. Pharmalink Regulatory Affairs Consulting Firm Opens New Offices in Washington, DC and Hartford, CT
Post Your Comments:
(Date:11/27/2015)... ... November 27, 2015 , ... Lizzie’s Lice Pickers just announced a ... customers 10% off of their purchase of lice treatment product. In addition, customers will ... to a company spokesperson. “Finding lice is a sure way to ruin the holidays, ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec Solutions announced today that ... (MSDSLUG). Recognized as Microsoft’s official group for end users of Dynamics SL ERP ... partners, industry experts and representatives. Intellitec Solutions’ membership status demonstrates their ongoing commitment ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and women ... healthcare organizations in the country. They have overseen financial turnarounds, shown commitment to ... the healthcare industry as a whole through their advocacy and professional efforts. , ...
(Date:11/26/2015)... ... , ... Inevitably when people think Thanksgiving, they also think Holiday sales and ... Friday and Cyber Monday massage chair sales to receive the best pricing ... to find the best massage chair deals, they can see all of the coupons ...
(Date:11/26/2015)... ... 26, 2015 , ... PRMA Plastic Surgery is updating their record books yet ... 6,000th free flap breast reconstruction surgery! , “What an accomplishment for the PRMA team, ... lives and it’s an honor to have served all of these women.” , PRMA ...
Breaking Medicine News(10 mins):
(Date:11/26/2015)... , Nov. 26, 2015 Research and ... of the "2016 Future Horizons and Growth ... Market: Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> --> ... of the Japanese therapeutic drug monitoring market, including ...
(Date:11/26/2015)... 2015 --> ... potential att använda SyMRI för att hitta ... patienter med multipel skleros (MS) eller hjärntumörmetastaser ... AB för att kunna använda SyMRI Research ... SyMRI kan man generera flera konstrastbilder från ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... of the "Self Administration of High Viscosity ... ) has announced the addition of ... report to their offering. --> ... the addition of the "Self Administration of ...
Breaking Medicine Technology: